Back to directory

Di-acetyl Creatine Ethyl Ester (Di-CEE)

A next-generation ester investigated for improved membrane permeability and neurological delivery, still confined to laboratory studies.

Di-acetyl modification aims to protect creatine through the GI tract and enhance blood-brain barrier transport before enzymatic cleavage releases active creatine.

Research-only
Improve brain uptake and stability
Not legally marketed as a supplement

Who it helps most

  • Currently limited to clinical trials investigating neurological outcomes

Limitations & cautions

  • No commercial availability
  • Safety profile still being established
  • Requires regulatory oversight

Promising neurological delivery

A 2017 Neuroscience Letters study showed enhanced brain uptake in rodent models, suggesting potential for treating creatine transporter deficiencies.

Why researchers care

Standard creatine struggles to cross the blood-brain barrier in certain deficiency syndromes. Di-acetyl modifications may ferry creatine more efficiently, offering hope for neurological indications.

Not for consumer use

Because dosing, toxicity, and long-term outcomes are unknown, di-CEE remains under investigation and should not appear in retail supplements.

Next steps in research

Future studies will need to confirm human pharmacokinetics, transporter interactions, and whether neurological improvements translate to functional outcomes.

Investigational—human dosing has not been established.

Restricted to licensed laboratories with ethics approval.

Compare with other creatine formats to find the best fit for your needs.

View all creatine types →
  • Neuroscience Letters – Di-acetyl creatine ethyl ester study

    Describes preclinical brain-delivery data.

    Visit source